Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL

Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukaemia

ecancer special issue on immunotherapy

PARP inhibitors in prostate cancer: A promise delivered

Targeting a KRAS neoantigen peptide vaccine to DNGR-1 dendritic cells

OncoAlert and ecancer weekly roundup for November 15 - 21, 2020

Updates in geriatric oncology from SIOG 2020

Clinical genomic testing in prostate cancer

PARP inhibitors for prostate cancer - Nurse's view

OncoAlert and ecancer weekly roundup for November 8 - 14, 2020